CYB003 (Cybin Inc.) is an oral deuterated psilocybin analogue proposed for use in conjunction with supportive psychotherapy for treatment of patients with moderate to severe major depressive disorder who have had an inadequate response to an antidepressant medication.
Publications
Hayes Publications are available through the Hayes Knowledge Center, a portal to world-class research and unbiased analyses on the clinical, financial, and risk impacts of emerging, controversial, and disruptive healthcare technologies.Every Hayes publication is developed by multidisciplinary teams of clinicians and scientists using rigorous methods grounded in internally recognized standards for systematic review and Health Technology Assessment. Learn more about these evidence resources and see sample titles below.
See below for some of our recent publications.
Fidanacogene Elaparvovec-dzkt (Beqvez; Pfizer Inc.) for Hemophilia B
Fidanacogene elaparvovec-dzkt (Beqvez; Pfizer Inc.) is a single-infusion gene therapy for the treatment of adults with moderate to severe hemophilia B who currently use factor IX prophylaxis therapy, or have current or historical life-threatening hemorrhage, or have repeated, serious spontaneous bleeding episodes, and do not have neutralizing antibodies to adeno-associated vi…
Ventura Interatrial Shunt (V-Wave Ltd.) for Heart Failure
The Ventura Interatrial Shunt (V-Wave Ltd.) is an investigational transcatheter interatrial shunt proposed for treatment of chronic heart failure.
Rusfertide (Protagonist Therapeutics Inc./Takeda Pharmaceutical Co. Ltd.) for Polycythemia Vera
Rusfertide (formerly PTG-300; Protagonist Therapeutics Inc./Takeda Pharmaceutical Co. Ltd.) is a subcutaneously injected hepcidin mimetic for the treatment of erythrocytosis associated with polycythemia vera.
Varipulse Pulsed Field Ablation (Biosense Webster Inc.) for Atrial Fibrillation
Varipulse is an investigational pulsed-field ablation system in development for treatment of paroxysmal atrial fibrillation.
Letetresgene Autoleucel (Adaptimmune Therapeutics PLC) for Advanced Synovial Sarcoma
Letetresgene autoleucel is an investigational autologous engineered T-cell therapy for the treatment of HLA-A*02 positive patients with advanced synovial sarcoma expressing the NY-ESO-1 antigen.
ReCET (Endogenex Inc.) Duodenal Mucosal Regeneration for Type 2 Diabetes
ReCET (Endogenex Inc.) is an investigational endoscopic procedure that uses pulsed electric fields to promote duodenal mucosal regeneration for treatment of type 2 diabetes that is poorly controlled with oral medications and/or insulin.
Intracept Intraosseous Nerve Ablation System (Relievant Medsystems Inc.) for Treatment of Adults With Low Back Pain
This report addresses whether full-text clinical studies, systematic reviews, and clinical practice guidelines and position statements support the use of the Intracept Intraosseous Nerve Ablation System (Relievant Medsystems Inc.) for improvement in back pain and function for adults with chronic low back pain thought to be due to vertebrogenic nerve pain.
Paradise Ultrasound Renal Denervation System (ReCor Medical Inc.) for Resistant Hypertension
This report addresses whether full-text clinical studies, systematic reviews, and clinical practice guidelines and position statements support the use of the Paradise Ultrasound Renal Denervation System (ReCor Medical Inc.) for reduction of blood pressure in patients with resistant hypertension.
Relyvrio (Sodium Phenylbutyrate/Taurursodiol; Amylyx Pharmaceuticals Inc.) for Amyotrophic Lateral Sclerosis (ALS)
Relyvrio (sodium phenylbutyrate/taurursodiol, formerly AMX0035; Amylyx Pharmaceuticals Inc.) is an oral fixed-dose combination drug indicated for the treatment of amyotrophic lateral sclerosis (ALS) in adults. As of April 4, 2024, Relyvrio has been withdrawn from the market.